ORTH ANDREW C. — SEC insider filings

SEC reporting owner CIK 1860010. 5 insider filings on record with FilingPulse; latest filed 2026-10-19.

Transaction summary — filings shown

Covers all 5 filings on record, filed 2022-03-01 to 2026-10-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Krystal Biotech, Inc. (KRYS)Chief Commercial Officer3—3 legs · 12,500 sh · $1,607,6355
CITY THERAPEUTICS, INC. (CTY)President & CEO, Director2——1

Insider filings — ORTH ANDREW C.

FiledFormIssuerReported transactionsSource
2026-10-194CITY THERAPEUTICS, INC. (CTY)Grant/award (A): 77,979 (derivative) @ $0EDGAR
2026-10-153CITY THERAPEUTICS, INC. (CTY)Holdings only — no transactions reportedEDGAR
2023-06-094Krystal Biotech, Inc. (KRYS)Option exercise (M): 12,500 @ $63.55 · Sale (S): 5,261 @ $128.10 · Sale (S): 6,906 @ $128.94 · Sale (S): 333 @ $129.70 · Option exercise (M): 12,500 (derivative) @ $0EDGAR
2023-02-284Krystal Biotech, Inc. (KRYS)Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0EDGAR
2022-03-014Krystal Biotech, Inc. (KRYS)Grant/award (A): 50,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2022-02-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1860010 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs